Clinical Trial Update: The Neurocognitive Sub-study of Encore1 [Phase 3]

View source ↗

Summary

This update reports the neurocognitive sub-study results from the ENCORE1 Phase 3 trial evaluating efavirenz dosing (400 mg vs 600 mg) in HIV treatment. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• Sustiva (efavirenz)

Snippet

Sponsor: Kirby Institute | Conditions: HIV | Phase 3 | Status: COMPLETED